Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells.
SD Gillies, EB Reilly, KM Lo… - Proceedings of the …, 1992 - National Acad Sciences
A genetically engineered fusion protein consisting of a chimeric anti-ganglioside GD2
antibody (ch14. 18) and interleukin 2 (IL2) was tested for its ability to enhance the killing of …
antibody (ch14. 18) and interleukin 2 (IL2) was tested for its ability to enhance the killing of …
Ganciclovir treatment of herpes simplex thymidine kinase-transduced primary T lymphocytes: an approach for specific in vivo donor T-cell depletion after bone marrow …
P Tiberghien, CW Reynolds, J Keller, S Spence… - 1994 - ashpublications.org
Allogeneic bone marrow transplantation (BMT) is associated with a severe complication--
graft-versus-host disease (GVHD). Although effectively preventing GVHD, ex vivo T …
graft-versus-host disease (GVHD). Although effectively preventing GVHD, ex vivo T …
Aldesleukin (recombinant interleukin-2) a review of its pharmacological properties, clinical efficacy and tolerability in patients with renal cell carcinoma
W Jeal, KL Goa - BioDrugs, 1997 - Springer
Synopsis Aldesleukin (recombinant interleukin-2), like endogenous interleukin-2 (IL-2), has
a variety of immunomodulatory properties. It is currently approved for intravenous use in …
a variety of immunomodulatory properties. It is currently approved for intravenous use in …
The immunobiological effects of interleukin-2 in vivo
RAJ Janssen, NH Mulder, T Hauw The… - Cancer Immunology …, 1994 - Springer
Interleukin-2 (IL-2) therapy is active mainly in melanoma and renal-cell carcinoma, and 20%
of the patients suffering from these cancers respond to IL-2 therapy, mostly with a partial …
of the patients suffering from these cancers respond to IL-2 therapy, mostly with a partial …
Lysis of malignant B cells from patients with B-chronic lymphocytic leukemia by autologous T cells activated with CD3 x CD19 bispecific antibodies in combination with …
H Bohlen, T Hopff, O Manzke, A Engert, D Kube… - 1993 - ashpublications.org
Bispecific antibodies (bi-MABs) can be used to target T cells to autologous tumor cells. It has
been shown that the activation of resting human T cells requires two independent signals …
been shown that the activation of resting human T cells requires two independent signals …
[图书][B] Фармакологическая коррекция иммуно-и гепатотоксических эффектов ксенобиотиков
НА Муфазалова, РШ Магазов, НН Егорова… - 2002 - elibrary.ru
В монографии обобщены данные литературы и результаты собственных
исследований по изучению возможности коррекции иммуно-и гепатотоксических …
исследований по изучению возможности коррекции иммуно-и гепатотоксических …
Recombinant antibody fusion proteins for cancer immunotherapy
RA Reisfeld, SD Gillies - Attempts to Understand Metastasis Formation III …, 1996 - Springer
The last decade has seen the extensive development of monoclonal antibodies (mAb)
combined with rapid advances in recombinant DNA technologies. These developments …
combined with rapid advances in recombinant DNA technologies. These developments …
Phase III study of low-dose intravenous OKT3 and subcutaneous interleukin-2 in metastatic cancer
J Buter, RAJ Janssen, A Martens, DT Sleijfer… - European Journal of …, 1993 - Elsevier
In a phase I II study the safety, immunostimulatory and antitumour effects of a combined
OKT3/interleukin 2 (IL-2) treatment was studied in 15 cancer patients who failed IL-2 …
OKT3/interleukin 2 (IL-2) treatment was studied in 15 cancer patients who failed IL-2 …
Adoptive immunotherapy of cancer: biological response modifiers and cytotoxic cell therapy
GG Hillman, GP Haas, WH Wahl, DM Callewaert - Biotherapy, 1992 - Springer
Immunotherapy has been developed for the treatment of metastatic cancers refractory to
conventional therapies. Immunotherapy utilizes immune cells and/or biological response …
conventional therapies. Immunotherapy utilizes immune cells and/or biological response …
Clinical and immunological effects of treatment with murine anti-CD3 monoclonal antibody along with interleukin 2 in patients with cancer.
JA Hank, M Albertini, OH Wesly, JH Schiller… - Clinical cancer research …, 1995 - AACR
Anti-CD3 mAb and interleukin 2 (IL-2) were used in a Phase I study to treat 29 patients with
cancer. The anti-CD3 was given as an iv bolus infusion over 10 min followed by two iv 96-h …
cancer. The anti-CD3 was given as an iv bolus infusion over 10 min followed by two iv 96-h …